Celldex Therapeutics (NASDAQ:CLDX) Sets New 1-Year Low – What’s Next?

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $20.91 and last traded at $22.26, with a volume of 920471 shares. The stock had previously closed at $21.91.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Up 1.6 %

The business’s 50 day simple moving average is $24.93 and its 200-day simple moving average is $30.08.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. ExodusPoint Capital Management LP bought a new position in Celldex Therapeutics during the fourth quarter worth about $436,000. Cinctive Capital Management LP raised its position in shares of Celldex Therapeutics by 140.6% in the 4th quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company’s stock valued at $2,055,000 after acquiring an additional 47,523 shares during the period. Bryce Point Capital LLC bought a new position in Celldex Therapeutics during the 4th quarter worth approximately $601,000. Headlands Technologies LLC bought a new position in Celldex Therapeutics during the 4th quarter worth approximately $81,000. Finally, JPMorgan Chase & Co. grew its holdings in Celldex Therapeutics by 103.3% during the fourth quarter. JPMorgan Chase & Co. now owns 85,545 shares of the biopharmaceutical company’s stock valued at $2,162,000 after purchasing an additional 43,470 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.